Effect of prolonged nitric oxide synthesis inhibition on plasma fibrinogen concentration in rats.
We examined whether nitro-L-arginine-methyl ester (L-NAME) causes a sustained elevation in plasma fibrinogen concentration in rats. Oral dosing of L-NAME (100 mg/kg per day) for 7 days significantly raised plasma fibrinogen concentration in rats. The increase in plasma fibrinogen, however, returned to control levels by the treatment for more than 7 days, in spite of progressive hypertension. Candesartan failed to reverse the transient hyperfibrinogenemia, indicating that the rise in plasma fibrinogen may occur through the mechanisms other than angiotensin II receptor activation. These data suggest that a prolonged L-NAME treatment does not cause chronic hyperfibrinogenemia in rats.
Sugimoto
K
K
Department of Clinical Pharmacology, Jichi Medical School, Kawachi-gun, Tochigi, Japan. ksugi@jichi.ac.jp
Tsuruoka
S
S
Fujimura
A
A
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005340:Fibrinogen / Q000378:metabolism*; D006973:Hypertension / Q000097:blood / Q000139:chemically induced; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D051381:Rats; D017208:Rats, Wistar; D013777:Tetrazoles
D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D004791:Enzyme Inhibitors; D013777:Tetrazoles; D009569:Nitric Oxide; D005340:Fibrinogen; D019001:Nitric Oxide Synthase; C077793:candesartan cilexetil; D019331:NG-Nitroarginine Methyl Ester